We have 15+ years of experience with activated mPEG manufacturing. We perform mPEG development at our R&D center in Hyderabad. Our team has extensive experience in synthesis, purification, and troubleshooting of mPEG derivatives and have technical capabilities in synthetic route design to incorporate various activating groups and help customize products as per end applications.
As a leading CDMO company/contract research organization, we understand customer requirements and customize our products to meet the client’s requirements. Currently, we serve multiple customers in various products such as diagnostic players, other mPEG suppliers, and big pharma using mPEG for advanced therapeutics. In addition, our backward integration of key raw materials makes it possible to ensure a sustainable quality of the final activated mPEG throughout the manufacturing process.
Key highlights of our services:
Various classes of mPEG derivatives we can handle
We are specialists in liner-activated mPEG. Our range of products includes various activating groups such as
- Methoxy PEG Maleimides (mPEG-Mal)
- Methoxy PEG pNP-Carbonates (p-Nitrophenyl Carbonate PEG)
- Methoxy PEG Propionaldehyde (mPEG-CHO)
- Methoxy PEG Amine (mPEG-NH2)
- Methoxy PEG NHS Ester
- Methoxy PEG Iodoacetamides
- Methoxy PEG Thiols (mPEG-SH)
We support the production of mPEG derivatives of molecular weight ranging from 2kDa, 5kDa, 10kDa, 20kDa, 30kDa, 40kDa, and 50kDa.
Activated mPEG manufacturing at Mirfield and Hyderabad
We help aid our customers with supplies for their development and clinical purposes. We manufacture mPEG derivatives from our UK and Hyderabad sites. Key features of our sites are as below:
- Annual capacity ~430 Kg (variable activating groups)
- Clean room manufacturing suite for medium-scale cGMP chemistry (1 - 300 Lit)
- Temperature range 0 to 150 °C
- Hastelloy hydrogenation or pressure reaction to 20 bars
- Stainless steel filter drier of 100 Lit capacity, 3 bars
- DCS computer control
- Heat transfer oil for accurate temperature control
Analytical capabilities
The analysis of large polymeric materials such as PEGs can be challenging. Our analytical lab is equipped with advanced equipment and analytical instruments to determine the quality of our highly pure mPEGs.
Also, we have a highly experienced analytical team who can characterize the compounds for any required impurity specifications and develop as well as validate such methods.
We perform all critical analytical tests in-house such as:
- Identification of compounds by NMR
- Analyzing impurities by HPLC
- Testing molecular weight and polydispersity by GPC
- Residual solvent content by GC
- Heavy metal analysis by ICP-OES
- The expected results would be +/- 10% variation
Why Aurigene mPEG Development Services?
Technical know-how to deliver even the most challenging specifications
Experience and legacy of having worked with big pharma clients
Analytical capabilities
UFDA audited facilities
Backward integration of mPEG alcohol
Other Services
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Methoxy Polyethylene Glycol (m-PEGs)
Aurigene Pharmaceutical Services is a leader in the synthesis of activated MethoxyPolyethyleneGlycol(m-PEGs), With a comprehensive product range and customized services. ...
Read More
Base mediated spirocyclization of quinazoline: one-step synthesis of spiro-isoindolinone dihydroquinazolinones
2020
A novel approach for the spiro-isoindolinone dihydroquinazolinones has been demonstrated from 2- aminobenzamide and 2-cyanomethyl benzoate in the presence of KHMDS as a base to get moderate yields. The reaction has been screened in various bases followed by solvents and a gram scale reaction has also been executed under the given conditions. Based on the controll...
Read More-
Ultrasound assisted rapid synthesis of mefenamic acid based indole derivatives under ligand free Cu-catalysis: Their pharmacological evaluation
2005
An improved and rapid synthesis of mefenamic acid based indole derivatives has been achieved via the ligand free Cu-catalyzed coupling-cyclization method under ultrasound irradiation. This simple, straightforward and inexpensive one-pot method involved the reaction of a terminal alkyne derived from mefenamic acid with 2- iodosulfanilides in the presence of CuI ...
Read More -
Formal synthesis of Cladospolide C & epi-Cladospolide C using R- (þ)-g-valerolactone as a chiral synthon
2005
The formal synthesis of Cladospolide-C and its analog is achieved by using enantiopure (R)-g evalerolactone 10. The significant points of this synthesis are the stereoselective dihydroxylation of a, bunsaturated ester 16 using Sharpless protocol, Wittig olefination of g evalerolactol 6 with triphenylphosphonium iodide salt 7, one pot selective oxidation ...
Read More -
Amberlite-15 promoted an unprecedented aza Michael rearrangement for one pot synthesis of dihydroquinazolinone compounds
2005
A new one pot multicomponent annulation strategy for the synthesis of various dihydroquinazolinone compounds has been developed using Amberlite-15 as a catalyst, giving good to moderate yields. In this reaction the substrate scope for amines and aldehydes was also investigated. The reaction has been checked on a large scale ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market